Business
‘Groundbreaking approach’: Imugene deal looks to smash solid tumours – Sydney Morning Herald
The $1.5 billion biotech will work with Nasdaq-listed firm Celularity in hopes of cracking the mystery of how to target tough…
Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will obliterate solid tumours.
The Sydney-based company, which has seen…
-
Noosa News21 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News24 hours agoFrom Dreamy Dining Rooms to Moody Basement Bars, Nearly 200 Venues Have Been Shortlisted for the 2025 Australian Interior Design Awards
-
Noosa News21 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General20 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off